BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone631-760-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$110,000.00
Profitability
Miscellaneous
Employees8
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable
BioRestorative Therapies (OTCMKTS:BRTX) Frequently Asked Questions
What is BioRestorative Therapies' stock symbol?
BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
How were BioRestorative Therapies' earnings last quarter?
BioRestorative Therapies Inc (OTCMKTS:BRTX) announced its earnings results on Wednesday, November, 13th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. View BioRestorative Therapies' Earnings History.
When is BioRestorative Therapies' next earnings date?
Has BioRestorative Therapies been receiving favorable news coverage?
News coverage about BRTX stock has trended extremely negative on Friday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioRestorative Therapies earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for BioRestorative Therapies.
Who are some of BioRestorative Therapies' key competitors?
Some companies that are related to BioRestorative Therapies include Fresenius Medical Care AG & Co. (FMS), Davita (DVA), Progyny (PGNY), Tivity Health (TVTY), HemaCare (HEMA), American Renal Associates (ARA), Catasys (CATS), Emmaus Life Sciences (EMMA), Baudax Bio (BXRX), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO) and American Caresource (GNOW).
What other stocks do shareholders of BioRestorative Therapies own?
Who are BioRestorative Therapies' key executives?
BioRestorative Therapies' management team includes the folowing people:
- Mr. Mark R. Weinreb, Chairman, CEO & Pres (Age 66)
- Mr. Robert Paccasassi, VP of Quality & Compliance (Age 50)
- Ms. Mandy D. Clyde, VP of Operations & Sec. (Age 37)
- Dr. Wayne J. Olan, Clinical Director of Regenerative & Spine Program and Member of Scientific Advisory Board
- Mr. Lance Alstodt, Exec. VP & Chief Strategy Officer (Age 48)
How do I buy shares of BioRestorative Therapies?
Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioRestorative Therapies' stock price today?
One share of BRTX stock can currently be purchased for approximately $0.00.
How big of a company is BioRestorative Therapies?
What is BioRestorative Therapies' official website?
How can I contact BioRestorative Therapies?
BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at 631-760-8100 or via email at [email protected]
MarketBeat Community Rating for BioRestorative Therapies (OTCMKTS BRTX)
MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote "Outperform" if you believe BRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
